CORRECTION

Correction to: The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens

Bo Jiang · Lin Gao · Su Dong · Qingxue Hou · Minghao Sun ·
Jingjie Zhang · Haotian Yu · Zhongyu Zhang · Dawei Sun

Published online: February 12, 2022
© Springer Healthcare Ltd., part of Springer Nature 2022

Correction to: Adv Ther
<https://doi.org/10.1007/s12325-021-01993-3>

In the original article the key summary points were published with incorrect text.

The correct Key Summary Points are:

The original article can be found online at <https://doi.org/10.1007/s12325-021-01993-3>.

B. Jiang · L. Gao · S. Dong · Q. Hou · M. Sun ·
J. Zhang · H. Yu · Z. Zhang · D. Sun (✉)
Ophthalmology Department, The Second Affiliated
Hospital of Harbin Medical University, 246 Xuefu
Road, Nangang District, Harbin 150001,
Heilongjiang, China
e-mail: sun.dawei@hotmail.com

Key Summary Points

Why carry out this study?

The outbreak of COVID-19 caused the interruption of anti-vascular endothelial growth factor (VEGF) treatment in patients with Neovascular age-related macular degeneration (nAMD), even resulting in the deterioration of previously stable patients. Therefore, we need to explore a regimen that is more beneficial to maintain the stability of patients

What was learned from the study?

The treat and extend (T&E) regimen can better maintain the stability of the treatment effect seen in patients with nAMD. After the COVID-19 interruption, the patients' visual acuities decreased less, the patients' lesions reactivated less, and the treatment was more regular. The COVID-19 pandemic is becoming increasingly normalized, and the T&E regimen should be a more advanced treatment option in the clinic

The original article has been updated.